The global Mice Model market gathered revenue around USD 12.7 billion in 2021 and market is set to grow USD 30.4 billion by the end of 2030 and is estimated to expand at a modest CAGR of 9.2% during the prediction period 2022 to 2030.
Growth Factors:
Mice have been one of the most important research tools for basic and applied research in biomedical sciences and continues to grow at a rapid rate. Besides providing precise correlation with human condition, the major advantage of mice models is the prospect of exploring precise gene-specific functions and various molecular events in a living organism. Combining mice models with advanced imaging technologies provide unique opportunities to understand the etiology and pathophysiology of human diseases. Furthermore, mice have been widely used in biomedical research to discover human diseases and to evaluate new drug candidates. Mouse research has led to major advances in treating a number of diseases and conditions. For instance, experiments on mice models resulted in efficacious treatments for acute promyelocytic leukemia, or APL, which was largely terminal.
North America was the largest market for mice model in 2021. The region dominated the global market due to substantial investments in the field, impressive economic growth, and increased research & development expenditure. Countries in Asia Pacific offer immense opportunities for research animal manufacturers, and the region is currently adopting advanced animal models for the research and drug discovery process. The mice model market in Asia Pacific is primarily dominated by multinational companies, particularly in transgenic and knockout mice models. These companies account for over 50% share of the market in countries such as Singapore, Malaysia, India, and China.
Report Scope of the Mice Model Market
|
Report Coverage |
Details |
|
Market Size |
US$ 30.4 Billion by 2030 |
|
Growth Rate |
CAGR of 9.2% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Type, Specialty, Service and Region, |
|
Companies Mentioned |
Charles River Laboratories, Crescendo Biologics Limited, Deltagen, Inc., GenOway S.A., Harlan Laboratories, Inc., ImmunoGenes AG, Taconic Biosciences, Inc., Lexicon Pharmaceuticals, SAGE Labs, The Jackson Laboratory, Taconic Biosciences, Inc., and TransGenic, Inc.. |
Personalized In Vivo Analysis Mice Models to Increase Demand For Mice Models in Personalized Medicine to Drive Market
Advances in gene technology, fueled by the need of fast, accurate treatment in the ever-evolving medical industry, are accelerating the growth of the global mice model market. Identification of genomic differences to predict drug resistance or drug response by the patients can offer scope to design a customized therapy tailored to the specific characteristics of a particular cancer. The Mouse Avatar and Co-clinical Trial concepts have the potential to revolutionize the drug development and health care process.
Inbred Mice Model Segment to Dominate Mice Model Market
In terms of model type, the global mice model market has been classified into transgenic mice model, hybrid/congenic mice model, knockout mice model, carcinogen-induced & spontaneous mice model, outbred mice model, inbred mice model, transplantation mice model, and conditioned/surgically modified mice model. The inbred mice model segment accounted for leading share of the global mice model market in 2021 due to advantages such as cost effectiveness and data reproducibility.
The hybrid/congenic segment is expected to expand at the fastest CAGR during the forecast period from 2017 to 2030 due to increase in applications in immunology, oncology, and cardiovascular studies.
Metabolism & Regulation to be Highly Lucrative Segment
Based on specialty, the global mice model market has been categorized into immunology, central nervous system, oncology, cardiovascular, diabetes, and metabolism & regulation. Metabolism & regulation was the largest segment of the global market in terms of revenue in 2021 due to increase in usage of mice model to study the diseases. The diabetes segment is likely to expand at the fastest CAGR during the forecast period due to rise in prevalence of the disease across the globe, particularly in developed countries.
Genetic Testing Segment to Dominate Market
In terms of service, the global mice model market has been divided into breeding & rederivation services, cryopreservation & cryorecovery services, quarantine services, genetic testing services, model in-licensing, in vivo & in vitro pharmacology services, genetically engineered model services, and other services. The genetic testing services segment dominated the global mice model market in 2020. Rise in importance of customized models in applied research as well as in the development and production of vital biomolecules is a major factor fueling the growth of the segment.
North America to Dominate Global Market
In terms of region, the global mice model market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global mice model market in 2021, followed by Europe. North America's dominance can be attributed to the presence of a large number of research institutions and biopharmaceutical companies that have been instrumental in driving the mice model market in the region.
Europe exhibits immense growth potential, as Western Europe has witnessed relatively higher adoption rate of rodents in the past few years.
Some of the prominent players in the Mice Model Market include:
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
Global Mice Model Market: Segmentation
Mice Model Market, by Type
Mice Model Market, by Specialty
Mice Model Market, by Service
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Mice Model Market Study:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Mice Model Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Mice Model Market Analysis and Forecast, 2017–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Developments
5.2. Overview of Mice Model Market
5.3. Technological Advancements
5.4. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
6. Global Mice Model Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2030
6.3.1. Transgenic Mice Model
6.3.2. Hybrid/Congenic Mice Model
6.3.3. Knockout Mice Model
6.3.4. Carcinogen-induced & Spontaneous Mice Model
6.3.5. Outbred Mice Model
6.3.6. Inbred Mice Model
6.3.7. Transplantation Mice Model
6.3.8. Conditioned/Surgically Modified Mice Model
6.4. Market Attractiveness Analysis, by Type
7. Global Mice Model Market Analysis and Forecast, by Specialty
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Specialty, 2017–2030
7.3.1. Immunology
7.3.2. Central Nervous System (CNS)
7.3.3. Oncology
7.3.4. Cardiovascular
7.3.5. Diabetes
7.3.6. Metabolism & Regulation
7.4. Market Attractiveness Analysis, by Specialty
8. Global Mice Model Market Analysis and Forecast, by Services
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Services, 2017–2030
8.3.1. Breeding & Rederivation Services
8.3.2. Cryopreservation & Cryorecovery Services
8.3.3. Quarantine Services
8.3.4. Genetic Testing Services
8.3.5. Model In-licensing Services
8.3.6. In Vivo & In Vitro Pharmacology Services
8.3.7. Genetically Engineered Model Services
8.3.8. Other Services (surgical and line rescue)
8.4. Market Attractiveness Analysis, by Services
9. Global Mice Model Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Mice Model Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2030
10.2.1. Transgenic Mice Model
10.2.2. Hybrid/Congenic Mice Model
10.2.3. Knockout Mice Model
10.2.4. Carcinogen-induced & Spontaneous Mice Model
10.2.5. Outbred Mice Model
10.2.6. Inbred Mice Model
10.2.7. Transplantation Mice Model
10.2.8. Conditioned/Surgically Modified Mice Model
10.3. Market Value Forecast, by Specialty, 2017–2030
10.3.1. Immunology
10.3.2. Central Nervous System (CNS)
10.3.3. Oncology
10.3.4. Cardiovascular
10.3.5. Diabetes
10.3.6. Metabolism & Regulation
10.4. Market Value Forecast, by Services, 2017–2030
10.4.1. Breeding & Rederivation Services
10.4.2. Cryopreservation & Cryorecovery Services
10.4.3. Quarantine Services
10.4.4. Genetic Testing Services
10.4.5. Model In-licensing Services
10.4.6. In Vivo & In Vitro Pharmacology Services
10.4.7. Genetically Engineered Model Services
10.4.8. Other Services (surgical and line rescue)
10.5. Market Value Forecast, by Country, 2017–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Specialty
10.6.3. By Services
10.6.4. By Country
11. Europe Mice Model Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2030
11.2.1. Transgenic Mice Model
11.2.2. Hybrid/Congenic Mice Model
11.2.3. Knockout Mice Model
11.2.4. Carcinogen-induced & Spontaneous Mice Model
11.2.5. Outbred Mice Model
11.2.6. Inbred Mice Model
11.2.7. Transplantation Mice Model
11.2.8. Conditioned/Surgically Modified Mice Model
11.3. Market Value Forecast, by Specialty, 2017–2030
11.3.1. Immunology
11.3.2. Central Nervous System (CNS)
11.3.3. Oncology
11.3.4. Cardiovascular
11.3.5. Diabetes
11.3.6. Metabolism & Regulation
11.4. Market Value Forecast, by Services, 2017–2030
11.4.1. Breeding & Rederivation Services
11.4.2. Cryopreservation & Cryorecovery Services
11.4.3. Quarantine Services
11.4.4. Genetic Testing Services
11.4.5. Model In-licensing Services
11.4.6. In Vivo & In Vitro Pharmacology Services
11.4.7. Genetically Engineered Model Services
11.4.8. Other Services (surgical and line rescue)
11.5. Market Value Forecast, by Country/Sub-region, 2017–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Specialty
11.6.3. By Services
11.6.4. By Country/Sub-region
12. Asia Pacific Mice Model Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2030
12.2.1. Transgenic Mice Model
12.2.2. Hybrid/Congenic Mice Model
12.2.3. Knockout Mice Model
12.2.4. Carcinogen-induced & Spontaneous Mice Model
12.2.5. Outbred Mice Model
12.2.6. Inbred Mice Model
12.2.7. Transplantation Mice Model
12.2.8. Conditioned/Surgically Modified Mice Model
12.3. Market Value Forecast, by Specialty, 2017–2030
12.3.1. Immunology
12.3.2. Central Nervous System (CNS)
12.3.3. Oncology
12.3.4. Cardiovascular
12.3.5. Diabetes
12.3.6. Metabolism & Regulation
12.4. Market Value Forecast, by Services, 2017–2030
12.4.1. Breeding & Rederivation Services
12.4.2. Cryopreservation & Cryorecovery Services
12.4.3. Quarantine Services
12.4.4. Genetic Testing Services
12.4.5. Model In-licensing Services
12.4.6. In Vivo & In Vitro Pharmacology Services
12.4.7. Genetically Engineered Model Services
12.4.8. Other Services (surgical and line rescue)
12.5. Market Value Forecast, by Country/Sub-region, 2017–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Specialty
12.6.3. By Services
12.6.4. By Country/Sub-region
13. Latin America Mice Model Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type , 2017–2030
13.2.1. Transgenic Mice Model
13.2.2. Hybrid/Congenic Mice Model
13.2.3. Knockout Mice Model
13.2.4. Carcinogen-induced & Spontaneous Mice Model
13.2.5. Outbred Mice Model
13.2.6. Inbred Mice Model
13.2.7. Transplantation Mice Model
13.2.8. Conditioned/Surgically Modified Mice Model
13.3. Market Value Forecast, by Specialty, 2017–2030
13.3.1. Immunology
13.3.2. Central Nervous System (CNS)
13.3.3. Oncology
13.3.4. Cardiovascular
13.3.5. Diabetes
13.3.6. Metabolism & Regulation
13.4. Market Value Forecast, by Services, 2017–2030
13.4.1. Breeding & Rederivation Services
13.4.2. Cryopreservation & Cryorecovery Services
13.4.3. Quarantine Services
13.4.4. Genetic Testing Services
13.4.5. Model In-licensing Services
13.4.6. In Vivo & In Vitro Pharmacology Services
13.4.7. Genetically Engineered Model Services
13.4.8. Other Services (surgical and line rescue)
13.5. Market Value Forecast, by Country/Sub-region, 2017–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Specialty
13.6.3. By Services
13.6.4. By Country/Sub-region
14. Middle East & Africa Mice Model Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2030
14.2.1. Transgenic Mice Model
14.2.2. Hybrid/Congenic Mice Model
14.2.3. Knockout Mice Model
14.2.4. Carcinogen-induced & Spontaneous Mice Model
14.2.5. Outbred Mice Model
14.2.6. Inbred Mice Model
14.2.7. Transplantation Mice Model
14.2.8. Conditioned/Surgically Modified Mice Model
14.3. Market Value Forecast, by Specialty, 2017–2030
14.3.1. Immunology
14.3.2. Central Nervous System (CNS)
14.3.3. Oncology
14.3.4. Cardiovascular
14.3.5. Diabetes
14.3.6. Metabolism & Regulation
14.4. Market Value Forecast, by Services, 2017–2030
14.4.1. Breeding & Rederivation Services
14.4.2. Cryopreservation & Cryorecovery Services
14.4.3. Quarantine Services
14.4.4. Genetic Testing Services
14.4.5. Model In-licensing Services
14.4.6. In Vivo & In Vitro Pharmacology Services
14.4.7. Genetically Engineered Model Services
14.4.8. Other Services (surgical and line rescue)
14.5. Market Value Forecast, by Country, 2017–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Specialty
14.6.3. By Services
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. Charles River Laboratories International, Inc.
15.2.1.1. Company Overview
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Business Strategies
15.2.1.5. Recent Developments
15.2.2. Crescendo Biologics Limited
15.2.2.1. Company Overview
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Business Strategies
15.2.2.5. Recent Developments
15.2.3. Deltagen, Inc.
15.2.3.1. Company Overview
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Business Strategies
15.2.3.5. Recent Developments
15.2.4. genOway S.A.
15.2.4.1. Company Overview
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Business Strategies
15.2.4.5. Recent Developments
15.2.5. Harbour Antibodies BV
15.2.5.1. Company Overview
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Business Strategies
15.2.5.5. Recent Developments
15.2.6. Harlan Laboratories, Inc.
15.2.6.1. Company Overview
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Business Strategies
15.2.6.5. Recent Developments
15.2.7. ImmunoGenes AG
15.2.7.1. Company Overview
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Business Strategies
15.2.7.5. Recent Developments
15.2.8. The Jackson Laboratory
15.2.8.1. Company Overview
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. Business Strategies
15.2.8.5. Recent Developments
15.2.9. Taconic Biosciences, Inc.
15.2.9.1. Company Overview
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. Business Strategies
15.2.9.5. Recent Developments
15.2.10. TransGenic, Inc.
15.2.10.1. Company Overview
15.2.10.2. Financial Overview
15.2.10.3. Product Portfolio
15.2.10.4. Business Strategies
15.2.10.5. Recent Developments
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers